What is cagrilintide and how does it work for weight loss?

GLP-1 peptide cagrilintide is a fixed-ratio co-formulation combining cagrilintide, a long-acting amylin analog, with semaglutide, a well-established GLP-1 receptor agonist. Cagrilintide (CAS: 1415456-99-3) acts as a dual amylin and calcitonin receptor agonist (DACRA), working alongside GLP-1 activity to suppress appetite, slow gastric emptying, and reduce glucagon secretion. Together, these two mechanisms produce additive weight reduction that exceeds either agent alone. In Phase II trials, the combination achieved up to 15.6% body weight reduction at 32 weeks—results that have placed this peptide pairing at the forefront of metabolic drug research.

Understanding Cagrisema: The Basics of Cagrilintide Peptide

What Is Cagrilintide?

It is a man-made, acylated amylin analogy with the formula C₁₈₄H₄₁₂N₅₉O₅₉S₂ and a molecular weight of 4409.01 g/mol. Its peptide sequence has a disulfide bridge inside between Cys4 and Cys9, as well as a C-18 fatty acid chain connected by α-glutamic acid. This structure gives cagrilintide a half-life long enough to support once-weekly subcutaneous dosing. This is a big improvement over native human amylin, which is quickly cleared by the kidneys.

How Does It Promote Weight Loss?

Cagrilintide binds to amylin and calcitonin receptors in the hypothalamus and brainstem, which are key parts of the energy balance system. This dual receptor activity makes you feel full for a longer time, which makes you eat less, and it also stops the release of glucagon after a meal, which helps control your blood sugar. When combined with semaglutide's GLP-1 receptor pathway, the two drugs work on overlapping but separate neural circuits, which makes them more effective at suppressing hunger than either one does on its own.

Pharmacokinetics at a Glance

Cagrilintide is absorbed reliably after being injected under the skin, and its Tmax is usually reached in 24 to 36 hours. The acyl chain helps albumin join, which makes its half-life in plasma last for about seven days. It is different from older amylin analogs because it is mostly cleared out of the body through proteolytic breakdown instead of renal filtering. It's important to note that the peptide stays soluble at neutral pH, which means it can be mixed with semaglutide without physical precipitation. This is a trait that pharmaceutical companies need to know when they are considering the feasibility of a formulation.

Clinical Evidence and Safety Profile of Cagrilintide

Key Trial Results

In Novo Nordisk's SCALE-like Phase II study, people who took GLP-1 peptide cagrilintide plus semaglutide 2.4 mg lost an average of 15.6% of their body weight over 32 weeks. This was compared to 5.1% of those who took semaglutide alone and 8.7% of those who took cagrilintide alone. These numbers show an important additive effect that can't be seen with either monotherapy alone.

Safety and Tolerability

The most common side effects seen in studies were nausea, vomiting, and reactions at the injection site. This is typical of the GLP-1 and amylin drug class as a whole. Serious side effects were very rare and about the same as in placebo groups. Starting with 0.25 mg and increasing the dose over 16 weeks has been shown to greatly reduce stomach side effects. This is an important thing for formulators to keep in mind when making dosing plans for patients.

Drug Interactions and Contraindications

Cagrilintide slows down the emptying of the stomach, which can change how quickly drugs taken by mouth are absorbed. This should be a part of any combination product plan made by the procurement and research and development teams. At this time, there are no signs that cytochrome P450 interacts with other drugs, but if it is taken with other drugs that lower blood sugar, it should be closely watched for hypoglycemia. Like the amylin class, there are some things that should not be done, like having a personal or family history of medullary thyroid cancer.

Cagrilintide vs Other GLP-1 Receptor Agonists: Making the Right Choice

Mechanism Differences

Semaglutide and liraglutide only work on GLP-1 receptors. Tirzepatide, on the other hand, also works on GIP receptors. Cagrilintide adds a third pathway—amylin and calcitonin receptor agonism—that works differently than GLP-1 pathways to target the area postrema and central appetite circuits. This unique process explains why adding cagrilintide to semaglutide makes it work better instead of making it work twice as well.

Efficacy Comparison in Weight Management

At 68 weeks, phase III data for semaglutide 2.4 mg showed that people had lost about 14.9% of their body weight. The combination of GLP-1 peptide cagrilintide and semaglutide achieved 15.6% after only 32 weeks in Phase II, which suggests that it might work better in the long term as trials go on. Tirzepatide caused a 22.5% weight loss at 72 weeks in SURMOUNT-1, but it works with different receptors than cagrisema.

Market Positioning for Procurement Teams

For drug makers and CRO/CDMO partners, cagrilintide is in a special spot because it's neither a replacement for GLP-1 therapy nor an easy add-on. Its dual receptor system makes the product stand out, which helps with patent positioning and intellectual property strategy. Instead of putting it with standard GLP-1 analogs, companies that are building weight management pipelines should look at it as a separate API category.

Procuring Cagrilintide Peptide: What B2B Clients Need to Know

Supplier Certification Requirements

To get research-grade cagrilintide, you have to go through a lot of paperwork. With every run, a good provider has to give you a Material Safety Data Sheet (MSDS), a Certificate of Analysis (COA), Mass Spectrometry data, and HPLC chromatograms. ISO14001 certifies environmental safety, while ISO9001 certifies quality control systems. For drug developers who are supervised by GMP or FDA, these documents can't be changed.

Before you place an order, here are the main quality standards you should check:

• Purity (HPLC): ≥98.0%, verifiable through batch-specific chromatogram data
• Peptide content: ≥80.0%, ensuring active fraction meets research thresholds
• Sequence integrity: Confirmed disulfide bridge between Cys4 and Cys9, validated by MS
• Storage compliance: -20°C ± 5°C in dry, sealed conditions to prevent degradation

All of these factors work together to tell if a batch is good for formulation study or developmental work. If materials are accepted that don't meet any one requirement, it could mean that data further down the line isn't valid.

Bulk Order and Logistics Considerations

When suppliers offer packaging from 1g to 1kg for GLP-1 peptide cagrilintide, it gives purchasing managers the freedom to match the order amount to the study phase. Lead time risk, which is a common problem in peptide buying, is lower when products are in stock and can be shipped right away. To make sure that international shipping rules are followed, especially for peptide APIs coming into the US market, customs paperwork and HS code classification must be looked over ahead of time.

Why Choose Cagrisema? Future Prospects and Strategic Advantages for Businesses

Expanding Market Demand

The world market for weight loss drugs is expected to be worth more than $100 billion by 2030. This is because obesity and type 2 diabetes are becoming more common. Most late-stage pharmaceutical funding goes to peptide-based treatments, especially multi-receptor agonists. Because Cagrisema is in this high-growth area, it makes sense for companies that are trying to build unique metabolic disease portfolios to focus on it.

Broad Application Scope

Cagrilintide is used in research for many different things, such as making pharmaceutical APIs, studying chemistry before it is tested on humans, and formulating new drugs. It helps client programs that fight obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). It is used by CROs and CDMOs. Universities and other research groups that study amylin receptor biology also have a steady need for high-purity, well-characterized material.

Long-Term Supply Chain Value

Supplier relationships that last a long time are valued by peptide APIs like cagrilintide. Assay reproducibility and regulation filing data are directly affected by batch-to-batch uniformity, which includes particle size, moisture content, and heavy metal profiles. Setting up a stable supply agreement early on in the development process protects against changes in raw materials that could cause IND filings or formulation lock to be delayed.

Conclusion

Cagrisema is a weight loss drug that is backed by strong science and shows promise in the clinic. It works by blocking amylin receptors and activating GLP-1 receptors, specifically through GLP-1 peptide cagrilintide. Pharmaceutical developers, CRO/CDMO partners, and research institutions need to find high-quality cagrilintide that has been tested for purity, has documentation that can be tracked, and has stable batch quality in order to get accurate research results. There is more and more proof, there is real demand in the market, and the first step in the procurement process is picking the right raw material provider.

FAQ

Q1: What is cagrilintide used for in research?

A: Cagrilintide is being studied as a long-acting amylin receptor activator for study into metabolic diseases and obesity. It is used as an API and a standard for preclinical studies, formulation development, and research into receptor pharmacology. Our research-grade material (CAS: 1415456-99-3) can only be used for scientific research and can't be sold to end users.

Q2: What purity grade is required for pharmaceutical research?

A: Most pharmaceutical research methods need reverse-phase HPLC to prove that the sample is at least 98% pure. This level is met by our cagrilintide, which comes with a full HPLC chromatogram, mass spectrometry results, and a certificate of analysis (COA) for each batch.

Q3: How should cagrilintide be stored?

A: Keep at -20°C ± 5°C in a dry, closed container that is out of the way of light and water. The lyophilized powder stays stable for a long time when kept in these settings. Do not use multiple freeze-thaw processes because they can weaken disulfide bonds.

Q4: Can cagrilintide be co-formulated with semaglutide?

A: Yes. Because it dissolves in neutral pH and binds to albumin, cagrilintide and semaglutide can be used together without any problems. Because of this property, the combination of cagrilintide and semaglutide (Cagrisema) was able to go through clinical trials without any problems with stability.

Q5: Is cagrilintide available in bulk quantities?

A: We package from 1g to 1kg in plastic bottles and can ship right away from stock. We help pharmaceutical companies, CROs, and research centers around the world buy things from other businesses.

Source Your Cagrilintide API from Xi'an Yihui

Since 2010, Xi'an Yihui Bio-technology Co., Ltd. has bought and sold high-purity peptide raw materials in more than 100 countries. As a reliable GLP-1 peptide cagrilintide supplier, we provide ≥98% HPLC-verified material, full batch paperwork, ISO9001/ISO14001 certification, and packaging ranging from 1g to 1kg. We also have these items in stock. You can get a quote or sample right now by emailing sales@yihuipharm.com.

References

1. Enebo, L. B., et al. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg for weight management." The Lancet. 2021.

2. Wilding, J. P. H., et al. "Once-weekly semaglutide in adults with overweight or obesity." New England Journal of Medicine. 2021.

3. Jastreboff, A. M., et al. "Tirzepatide once weekly for the treatment of obesity." New England Journal of Medicine. 2022.

4. Marso, S. P., et al. "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes." New England Journal of Medicine. 2016.

5. Ratner, R. E., et al. "Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus." Diabetic Medicine. 2004.

6. Ryan, D., et al. "Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight management." Obesity Reviews. 2022.